Dr Thomas Bieringer to become INVITE md

Predecessor Michael Lorenz moves to Bayer MaterialScience

Dr Thomas Bieringer has been appointed managing director of INVITE GmbH. He takes up the role on 1 July. The German research company works on new production concepts for the "Factory of the Future".

Bieringer, a physicist, succeeds Michael Lorenz, who has been responsible as managing director for the technology centre at Chempark Leverkusen since the joint venture between Bayer Technology Services (BTS) and Technical University Dortmund was established in 2010. Lorenz played a major role in the concept and development of the technology centre, which will be officially inaugurated in September. He will assume new duties at the Industrial Operations unit of Bayer MaterialScience.

Bieringer, who obtained his PhD from University of Bayreuth in the field of optical data storage in polymers, has been working at Bayer since 1997. He has headed the Innovation section within the Corporate Development department of the Corporate Centre since 2004. As spokesman of the Bayer Innovation Community, he was largely involved in the strategic alignment of the research units of the Bayer subgroups.

You may also like

Research & Development

Recursion adds new chemical entity targeting fibrotic diseases to late discovery pipeline

Potential first-in-class molecule with novel target inlicensed from collaboration with Bayer
Regulatory

Pistoia Alliance announces data management toolkit

Roche, AstraZeneca and Bayer supports FAIR Implementation project to improve data management and better AI and machine learning for the "Lab of the Future"
Design & Build

Bayer chooses Fluor and GE Healthcare for new cell culture technology centre

Company will invest US$150 million in new California facility expected to be ready for clinical production in late 2021
Media

TissUse establishes a multi-organ model for risk assessment with Bayer

The biotechnology company has signed a collaboration agreement with the pharmaceutical and life sciences company to develop a liver-endocrine tissue assay
Drug Delivery

Bayer and DelSiTech link up to develop new ophthalmology drug delivery technology

Agreement highlights the potential of biodegradable silica material in demanding drug delivery applications
Research & Development

Casebia Therapeutics establishes operations in Cambridge (MA, USA)

Hiring is underway and efforts have begun on haematology and ophthalmology programmes
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

ADCs: a more effective, less harmful, targeted approach

Antibody-drug conjugates could hold the key to delivering highly potent anticancer drugs more accurately to the tumour site with less damage to healthy cells
Subscribe now